Advanced search
1 file | 122.79 KB

Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia

Author
Organization
Abstract
Pipamperon is a potent neuroleptic drug with many side effects, including prolongation of the QT interval. We report a case of a child treated for leukemia in which prolongation of the QT interval was observed. Physicians and pharmacists should be cautious for drug-drug interactions when pipamperon is prescribed, especially in combination with other QT-prolongating agents. Alternative strategies should be used whenever possible.
Keywords
Pipamperon, ondansetron, drug-drug interaction, leukemia, TORSADE-DE-POINTES, INTERVAL, QTC

Downloads

  • Drugdrug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 122.79 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Bauters, Tieneke, Sarah Buts, Maria Bordon Cueto De Braem, and Genevieve Laureys. 2018. “Drug-drug Interaction Related to the Use of Pipamperon and Ondansetron in a Child Treated for Leukemia.” Journal of Oncology Pharmacy Practice 24 (7): 537–539.
APA
Bauters, Tieneke, Buts, S., Bordon Cueto De Braem, M., & Laureys, G. (2018). Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 24(7), 537–539.
Vancouver
1.
Bauters T, Buts S, Bordon Cueto De Braem M, Laureys G. Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia. JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2018;24(7):537–9.
MLA
Bauters, Tieneke, Sarah Buts, Maria Bordon Cueto De Braem, et al. “Drug-drug Interaction Related to the Use of Pipamperon and Ondansetron in a Child Treated for Leukemia.” JOURNAL OF ONCOLOGY PHARMACY PRACTICE 24.7 (2018): 537–539. Print.
@article{8563800,
  abstract     = {Pipamperon is a potent neuroleptic drug with many side effects, including prolongation of the QT interval. We report a case of a child treated for leukemia in which prolongation of the QT interval was observed. Physicians and pharmacists should be cautious for drug-drug interactions when pipamperon is prescribed, especially in combination with other QT-prolongating agents. Alternative strategies should be used whenever possible.},
  author       = {Bauters, Tieneke and Buts, Sarah and Bordon Cueto De Braem, Maria and Laureys, Genevieve},
  issn         = {1078-1552},
  journal      = {JOURNAL OF ONCOLOGY PHARMACY PRACTICE},
  language     = {eng},
  number       = {7},
  pages        = {537--539},
  title        = {Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia},
  url          = {http://dx.doi.org/10.1177/1078155217717325},
  volume       = {24},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: